SK biopharmaceuticals Co., Ltd. (에스케이바이오팜 주식회사)
KOSPI Stock Code: 326030 | DART Corp Code: 00878696
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | SK biopharmaceuticals Co., Ltd. |
|---|---|
| Korean legal name | 에스케이바이오팜 주식회사 |
| Alternate names | 에스케이바이오팜 |
| Market | KOSPI |
| Stock Code | 326030 |
| DART Corp Code | 00878696 |
| CEO | 이동훈 |
| Business Registration No. | 1018662394 |
| Corporate Registration No. | 1101114570720 |
| Established Date | 2011-04-01 |
| Fiscal Month | 12 |
| KSIC Industry Code | 7011 |
| Address (KO) | 경기도 성남시 분당구 판교역로 221 |
| Homepage | https://www.skbp.com/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773 |
| verified_at | 2026-11-01T02:26:02.813Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 706,740,960,308 | KRW 547,596,283,214 |
| Operating Income (영업이익) | KRW 203,938,471,064 | KRW 96,339,659,521 |
| Net Income (당기순이익) | KRW 253,253,847,619 | KRW 226,973,435,375 |
| Total Assets (자산총계) | KRW 1,198,308,575,535 | KRW 1,036,810,779,623 |
| Total Liabilities (부채총계) | KRW 372,039,049,706 | KRW 462,826,530,311 |
| Total Equity (자본총계) | KRW 826,269,525,829 | KRW 573,984,249,312 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-09-23 | 20260923800342 | Conclusion of Single Sales Contract or Supply Contract | 단일판매ㆍ공급계약체결 | 에스케이바이오팜 |
2026-09-17 | 20260917800227 | Material Business Matters Related to Investment Decisions | 투자판단관련주요경영사항 | 에스케이바이오팜 |
2026-09-15 | 20260915800235 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 에스케이바이오팜 |
2026-09-15 | 20260915000042 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 이동훈 |
2026-09-15 | 20260915000040 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 유창호 |
2026-09-14 | 20260914800220 | Conclusion of Single Sales Contract or Supply Contract | 단일판매ㆍ공급계약체결 | 에스케이바이오팜 |
2026-09-10 | 20260910800702 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 에스케이바이오팜 |
2026-09-10 | 20260910800675 | Material Business Matters Related to Investment Decisions (뇌전증 신약 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 수령) | 투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 수령) | 에스케이바이오팜 |
2026-08-31 | 20260831800329 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 에스케이바이오팜 |
2026-08-31 | 20260831000159 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 이동훈 |
2026-08-31 | 20260831000145 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 유창호 |
2026-08-27 | 20260827000583 | Disclosure of Current Status of Large-scale Business Groups [Quarterly Disclosure (For individual company)] | 대규모기업집단현황공시[분기별공시(개별회사용)] | 에스케이바이오팜 |
2026-08-26 | 20260826000365 | [Added attachment]Report on Major Issues (중요한자산양수도결정(기타)) | [첨부추가]주요사항보고서(중요한자산양수도결정(기타)) | 에스케이바이오팜 |
2026-08-26 | 20260826800162 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 에스케이바이오팜 |
2026-08-26 | 20260826800139 | Material Business Matters Related to Investment Decisions (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약) | 투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약) | 에스케이바이오팜 |
2026-08-18 | 20260818800303 | Conclusion of Single Sales Contract or Supply Contract | 단일판매ㆍ공급계약체결 | 에스케이바이오팜 |
2026-08-14 | 20260814002274 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 에스케이바이오팜 |
2026-08-14 | 20260814000403 | Matters concerning payment amount for each payment method-payment period and Dispute Resolution Organization | 지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 | 에스케이바이오팜 |
2026-08-05 | 20260805800117 | Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | 연결재무제표기준영업(잠정)실적(공정공시) | 에스케이바이오팜 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773 | verified_at: 2026-11-01T02:26:02.813Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.